Effect of Epidermal Growth Factor Receptor Inhibitors on Magnesium Homeostasis in Patients With Cancer
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving epidermal growth factor receptor inhibitors may help doctors understand the effect of epidermal growth factor receptor inhibitors on magnesium levels in the body.
PURPOSE: This laboratory study is looking at the effect of epidermal growth factor receptor inhibitors on magnesium homeostasis in patients with cancer.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Pilot Study of the Effects of Epidermal Growth Factor Receptor (EGFR) Inhibitors on Magnesium Homeostasis|
- Effects of EGFR inhibitors on magnesium homeostasis [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||May 2006|
|Study Completion Date:||February 2009|
|Primary Completion Date:||March 2008 (Final data collection date for primary outcome measure)|
Other: laboratory biomarker analysis
- Determine the effects of EGFR inhibitors on magnesium homeostasis in patients with cancer.
OUTLINE: This is a pilot study.
Patients undergo blood and urine sample collection at baseline and at 2, 4, and 8 weeks during treatment.
After finishing treatment, patients are followed periodically for up to 10 weeks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00898027
|Principal Investigator:||Laura Goff, MD||Vanderbilt-Ingram Cancer Center|